Mark Elliott Boulding, Executive VP AND CLO at PTC THERAPEUTICS, INC. (PTCT), sold 5,894 shares at $69.29 ($409K) on 2026-02-17, disclosed to the SEC on 2026-02-19.
Seasonal sale ($409k) by Executive VP AND CLO — this insider has traded PTCT in February in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $69.29 | 2,811 | $195K | 47.7% |
| 2 | $70.13 | 2 | $140 | 0.0% |
| 3 | $69.36 | 3,081 | $214K | 52.3% |
| Total | $69.33 avg | 5,894 | $409K | 100% |
| Filing → |
| PTCT | SELL | 2026-08-19 | $204K | — | Filing → |
| PTCT | SELL | 2026-07-08 | $432K | — | Filing → |
| PTCT | SELL | 2026-06-22 | $823K | — | Filing → |